However, uncertainty exists as to which strategies in terms of amount, delivery devices and timing are clinically effective. Perioperative oxygen administration has been proposed as a potential strategy to prevent and treat hypoxaemia and reduce complications, such as surgical site infections, pulmonary complications and mortality. Oxygen is routinely given to patients during and after surgery. In addition to identifying certain areas of insufficiency, these findings indicate the need to justify or modify AMSTAR 2’s rating rules. The low ratings for these potential high-quality heart failure-related SRs and MAs challenge the discrimination capacity of AMSTAR 2. Overall, 79 studies were of “critically low quality” and two were of “low quality.” These findings were attributed to insufficiency in the following critical domains: a priori protocols (compliance rate, 5%), complete list of exclusions with justification (5%), risk of bias assessment (69%), meta-analysis methodology (78%), and investigation of publication bias (60%). On the basis of the performance in these 16 domains with different weights, overall ratings were generated, and the quality was determined to be “high,” “moderate,” “low,” or “critically low.”Įighty-one heart failure-related SRs with MAs were included. Seven domains were deemed critical for high-quality studies. The included studies were assessed on the basis of 16 domains. We aimed to perform the first AMSTAR 2-based quality assessment of heart failure-related studies.Įleven high-impact journals were searched from 2009 to 2019. The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. Further work is needed to explore how closely published SRs adhere to the planned methods, whether greater pre-specification of outcomes prevents selective inclusion and reporting of study results, and whether registered SRs address necessary questions.
WEBSITE X5 EVOLUTION 9 UNREGISTERED VERSION PROBLEM REGISTRATION
Registration of SRs in PROSPERO increased rapidly between 20, thus benefiting users of health evidence who want to know about ongoing SRs. timing, effect measures) was not pre-specified in 44/150 records (29%).
Any information about the primary outcome other than the domain (e.g. The 150 registered SRs addressed 18 different health areas. In the random sample of 150 registered SRs, the majority were focused on a therapeutic question (78/150 ), while only a few focused on a diagnostic/prognostic question (11/150 ).
In the year preceding October 10, 2017, the PROSPERO website received more than 1.75 million page views. There has been a 10-fold increase in registrations, from 63 SRs per month in 2012 to 800 per month in 2017. ResultsAs of October 10, 2017, there were 26,535 SRs registered in PROSPERO guided by current monthly submission rates, we anticipate this figure will reach over 30,000 by the end of 2017. therapeutic, diagnostic), health area addressed, funding source and completeness of outcome pre-specification in a random sample of 150 records of SRs registered in PROSPERO between Apand September 30, 2017. One author collected data on the focus of the SR (e.g. The PROSPERO database managers provided us with data on the annual and cumulative number of SR registrations up to October 10, 2017, and the number of visits to the PROSPERO website over the year preceding October 10, 2017. We also aimed to explore the epidemiological characteristics of and completeness of primary outcome pre-specification in a sample of PROSPERO records from 2017. We aimed to investigate the number of PROSPERO registrations from inception to 2017, and website usage in the last year.
There have been few investigations of the content and use of the database. The International Prospective Register of Systematic Reviews (PROSPERO) was launched in February 2011 to increase transparency of systematic reviews (SRs).